A B S T R A C T We evaluated the interaction of [3H]1,25(0H)2D3 with skin fibroblasts cultured from normal subjects or from affected members of six kindreds with rickets and resistance to 1-alpha, 25(OH)2D [1,25(OH)2D]. We analyzed two aspects of the radioligand interaction; nuclear uptake with dispersed, intact cells at 370C and binding at 0C with soluble extract ("cytosol") prepared from cells disrupted in buffer containing 300 mM KCl and 10 mM sodium molybdate.
INTRODUCTION
In 1937 Albright and co-workers suggested that rickets might arise in some cases not from deficiency of vitamin D but from inadequate action of vitamin D (1) . Deficiency rickets is associated typically with hypocalcemia and secondary hyperparathyroidism. Although resistant rickets in Albright's and in many other patients has been associated with hypophosphatemia but not hypocalcemia,' Prader reported that some pal The terms resistance, insensitivity, and unresponsiveness are sometimes used interchangeably. We use resistance in its broadest sense to describe a state where normal levels of a factor are not associated with a normal biologic effect. Responsiveness is the maximal attainable affect from high dosage of a factor. Sensitivity varies as inverse of the dosage of a factor to give half of the maximal attainable effect. tients exhibited early onset hypocalcemic rickets without the common causes (D deficiency, renal failure, intestinal malabsorption) (2) . This has been termed vitamin D-dependency or pseudo-vitamin D-deficiency, and it sometimes occurs on a hereditary basis. Vitamin D action requires metabolism by hydroxylations at positions 25 and 1-alpha to yield 1,25(OH)2D (3) . Many patients with hereditary vitamin D-dependency are thought to have a defect in I-alpha-hydroxylation of 25(OH)D (4); however, some have been recognized to exhibit long-term and profound resistance to 1,25(OH)2D itself (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) . The following features have characterized patients with severe resistance to 1,25(OH)2D: hypocalcemia, secondary hyperparathyroidism, osteomalacia or rickets with normal vitamin D intake, and normal or high circulating levels of 1,25(OH)2D. In most of these latter cases there has been data suggesting autosomal recessive transmission of the resistance. However, subtle clinical and biochemical findings have suggested heterogeneity in the underlying defects. Alopecia is found in affected members of some (7, 9, 10, 12, 13, 15) but not all (5, 6, 8, 11, 14) kindreds; in one patient there was hyperphosphatemia and undetectable levels of 24,25(OH)2D (10) ; and one patient failed to achieve eucalcemia even with serum 1,25(OH)2D at concentrations 100 times normal for 12 mo. 2 Like the true steroidal hormones, 1,25(OH)2D acts in the nucleus of target cells (16) ; this requires a multistep process involving hormone receptors, localization of receptor and hormone in the nucleus, and induction of specific messenger RNA synthesis. In theory, resistance to 1,25(OH)2D could arise at any of several points in this process. Indeed, genetic defects in the response system for androgenic steroids (17) and for glucocorticoids (18) have resulted from lesions at several analogous loci.
Recently, several laboratories have described putative receptors for 1,25(OH)2D in cultured skin fibroblasts (19, 20) . Skin fibroblasts cultured from 1,25-(OH)2D-resistant members of two kindreds were shown to have similar defective nuclear uptake of [3H]-1,25(OH)2D3 (21) . While clinical features distinguished affected members in these latter two kindreds, the nuclear uptake assay did not uncover evidence of heterogeneity in the associated cellular defects. We have now extended our studies on whole-cell nuclear uptake of 1,25(OH)2D in cultured fibroblasts to include four additional affected patients representing four unrelated kindreds. In I In kindreds 1 and 2 both affected siblings were evaluated in detail, and the features were consistent within each kindred. In kindreds 3, 4, and 5 the affected siblings had died before evaluation of the studied patient. § Numerical data are not cited because of differences in normal ranges related to assay methods, patient age, and patient sex. 11 Values in the "normal" range may be inappropriate, resulting from defective receptormediated induction of 25(OH)D 24-hydroxylase by high circulating levels of 1,25(OH)2D.
procedure once, radioactivity associated with the nuclei was determined (20) . Binding of [3H]1,25(OH)2D3 to soluble extracts from cells. All procedures were performed with solutions maintained at 0-40C. Cells were grown and harvested as above, washed in phosphate-buffered saline, and suspended in buffer A (10 mM Tris-HCl pH 7.4, 300 mM KCI, 10 mM sodium molybdate, 1.5 mM EDTA, 1.0 mM dithiothreitol, and aprotinin; 500 Kallikrein Inactivator Units/ml) at a cell concentration of 3-6 X (10)6/ml.
We included 300 mM KCl and 10 mM sodium molybdate in the buffer because of their stabilizing effect on activity of the receptor (22) . The suspension was treated with three 5-s pulses from a sonicator (Heat Systems-Ultra Sonic Inc W-375, Plainview, NY) with microtip set at a gain of 4 on a 50% duty cycle. The sonicate was centrifuged at 100,000 g for 60 min. The supernate was saved and will be referred to as "cytosol". 15 h to reach a plateau at the lowest concentrations of radioligand evaluated (24) . Bound and unbound radioli-gand were separated with hydroxylapatite (25) . In brief, hydroxylapatite was prepared in buffer A, washed repeatedly, and stored overnight at 0-4°C. A 50% slurry was prepared by adding a volume of buffer A equal to the settled volume of the resin. Aliquots (0.4 ml) of the slurry were added to cytosol at the end of incubation. Samples were agitated at 5-min intervals for 15 min. Samples were then centrifuged and pellets were washed three times by suspension and sedimentation through buffer A containing 0.5% Triton X-100.
[3H]1,25(OH)D3 was extracted from the washed pellets with 2 ml absolute ethanol at 0-4°C for 15 min. Aliquots (1 ml) of supernate were assayed for radioactivity in 6.5 ml Aquasol.
Sucrose density gradient centrifugation of nuclear extracts. Cells were harvested and incubated with [3H]-1,25(OH)2D3 (0.9-1.5 X [10f-9M) with or without I jIM 1,25(OH)2D3 as indicated above. All subsequent procedures were performed with solutions maintained at 0-4°C. Cells were then washed twice with phosphate-buffered saline, suspended in buffer A without KCl, and homogenized with a tightly fitting Dounce homogenizer. After centrifugation at 1,000 g for 10 min, the crude nuclear pellet was suspended in 0.5 ml buffer A and sonicated as described above. To remove unbound [3H]1,25(OH)2D3 without diluting extracts, pellets were prepared by centrifuging 0.5 ml of dextrancoated charcoal suspension (0.25%[wt/wt] Norit A, 0.0024% [wt/wt] dextran T-70 in 0.01 M Tris-HCI, pH 7.4) at 1,000 g for 10 min. Then 0.5 ml of the nuclear extract was added, mixed, and incubated for 10 min. Suspensions were centrifuged 10 min at 1,000 g at 4°C, and 0.35 ml of supernate with ["4Clovalbumin was layered on a 5-20% sucrose gradient (total volume 4.3 ml) in buffer A. This was centrifuged 17 h at 0°C at 250,000 g using a Beckman L5-65 centrifuge and an SW 60 rotor. Six drop fractions were collected from the bottom of the gradient, added to 0.5 ml H20 and 5 ml Aquasol, and assayed for radioactivity.
Sucrose density gradient centrifugation of cytosol:3 Cytosol was incubated for 3 h at 0-40C in a final volume of 0.5 ml of buffer A with [3H]1,25(OH)2D3 (0.9-1.5 nM) with or without 1 1sM 1,25(OH)2D3. Unbound radioligand was removed as described above for nuclear extracts, and sedimentation velocity of radioligand in sucrose gradients was analyzed as above.
Cells in suspension were counted with a hemocytometer. Protein was determined by the method of Lowry et al. (26) . High affinity binding was analyzed by the method of Scatchard (27) (Table II) . Similar capacity (9,100±1,100 nuclear uptake sites per cell) and affinity (0.4±0.1 nM) (mean±1 SE from 10 experiments) were obtained with MCF-7 cells from a human breast cancer (28) .
In cells from patient 3 the capacity and affinity of nuclear uptake were normal. In cells from the remaining seven patients nuclear uptake was defective; (Table III) .
Sedimentation velocity of cytosol-associated radioligand. Sucrose gradient analysis of radioligand after incubation with cytosol3 extract revealed a single peak at -3.7S from normal fibroblasts (Fig. 4) and from MCF-7 cells (not shown).
Sedimentation velocities obtained with cytosol from fibroblasts of patients 3 and 4 were indistinguishable from normal (Fig. 4) . With cytosol from patient 4 the area of the saturable peak at 3.7S was 10% of normal. In similar manner the sedimentation velocity of cytosol-associated radioligand was normal for patients lb and 2b (not shown). Saturable binding was not detectable in the density gradient of the cytosol from fibroblasts of patients 5 (19, 20) . Neither donor age nor cell passage number have major affect on receptor-mediated nuclear uptake of 1,25(OH)2D3 in cultured skin fibroblasts (20, 21) . Among six kindreds with presumably hereditary resistance to 1 ,25(OH)2D, we have observed three patterns with the whole-cell nuclear uptake assay: normal capacity with normal affinity (kindred 3), decreased capacity with normal affinity (kindred 4), or unmeasurable capacity and affinity (kindreds 1, 2, 5, and 6). Our present study shows that cytosol of fibroblasts cultured from normal skin binds [3H]1,25(OH)2D3 with capacity and affinity similar to those in MCF-7 cancer cells (28) and in cells cultured from several organs known to be targets for 1,25(OH)2D3 (bone [29] and kidney [30] ). The similar 1,25(OH)2D3-capacity observed for nuclear uptake and for cytosol binding suggests that the cytosol binding assay is an index of the same processes as the nuclear uptake assay, and that a limiting factor in high affinity nuclear uptake of 1,25(OH)2D is the number of intracellular receptors for 1,25(OH)2D. The correlations between data from the nuclear uptake and cytosol binding assays in kindreds 3-6 represent independent evidence that the cytosol binding assay provides a direct analysis of one or more components in the nuclear uptake process.
The two assays that we have employed (whole-cell nuclear uptake and cytosol binding of [3H]1,25(OH)2D3) provide complementary information. Whole-cell nuclear uptake reflects a more distal aspect of the effector system for 1,25(OH)2D; it is thus more useful for screening of cells and for assessment of certain events distal to binding in cytosol. Affected members from five of six kindreds exhibited deficient whole-cell nuclear uptake. Analysis of cytosol binding provides additional insight into certain lesions associated with deficient nuclear uptake. In our study, deficient nuclear uptake has been associated with three different patterns in the cytosol binding assay; unmeasurable nuclear uptake was associated with normal (kindreds 1 and 2) or with unmeasurable (kindreds 5 and 6) cytosol binding while 90% decrease in nuclear uptake capacity was associated with 90% decrease in cytosol binding capacity (kindred 4).
Sucrose density gradient analysis of nucleus-associated or of cytosol-associated radioligand has not provided major additional insight into the nature of defects but has shown that the radioligand taken up in nucleus or bound to cytosol with high affinity migrates with the same sedimentation velocity whether derived from patient cells or normal cells.
Cultured (17) . Alternatively, the defect of 1,25(OH)2D action in patient 3 may be proximal to chromatin activation but may not be expressed with assay methods we have used to date. Patient 3 showed the unusual feature of achieving marked improvement in hypocalcemia while being treated with 24,25(OH)2D3 (10). This had been administered because circulating levels of 24,25(OH)2D were undetectable (<0.4 ng/ml vs. normal of 1.5 to 2.5 ng/ml). If the underlying defect in this kindred is a deficiency of a modulator (such as 24,25(OH)2D) of target tissues for 1,25(OH)2D, then the secondary defect in the 1,25(OH)2D effector system might not be expressed in cultured skin fibroblasts. Normal whole-cell nuclear uptake has been reported for one other patient with resistance to 1,25(OH)2D (34) .
Fibroblasts cultured from affected members of two kindred pairs (kindreds 5 and 6; kindreds 1 and 2) exhibited similar abnormal patterns in their interactions with 1,25(OH)2D3; for each kindred pair, there were clinical features that distinguished affected members of one family from affected members of the other (Table I) . Thus the data obtained in vivo (Table I ) and in vitro (Tables II and III) indicate that resistance to 1,25(OH)2D3 in these six kindreds reflects five or perhaps six distinct mutations in the genes that determine the effector system for 1,25(OH)2D. Our analyses do not establish whether the distinct molecular defects are localized to the receptor molecule(s) or to processes closely associated with them.
The recognition that the molecular defects in kindreds with resistance to 1,25(OH)2D are heterogeneous has provided potential explanations for some of the clinical diversity among these kindreds. Certain features, such as the frequently associated total alopecia, remain 
